$IONS

Morningstar says US-listed earnings are set to rise 44.6% in Q2 vs Q1, with 55% of reported stocks beating FactSet by at least 5%. It screens for undervalued “earnings crushers” meeting criteria and names six: ALB, TEAM, BAX, KMX, IONS, SNY, each with reported EPS and revenue vs consensus and discounts to fair value.

Ionis Pharmaceuticals (IONS) shares fell about 30% YTD after Ark Genomic Revolution ETF bought $15.3M of IONS shares following late-stage eplontersen failure. Q2 revenue was $268M, down 41% but up 56% excluding a $280M Ono upfront. FDA approved Tryngolza for severe hypertriglyceridemia; label expanded to over 3M patients. Guidance reiterated $875M to $900M; William Blair sees $3B peak sales.

Morningstar says 55% of US-listed stocks it covers beat FactSet earnings by at least 5% as of Aug. 11. It screened for six undervalued “earnings crushers” with 10%+ EPS beats and 5%+ revenue beats, including Albemarle, Atlassian, Baxter International, CarMax, Ionis Pharmaceuticals, and Sanofi, citing EPS, revenue, Morningstar ratings, and discounts to fair value.

Ionis Pharmaceuticals (IONS) shares fell about 30% YTD after its heart drug eplontersen failed to show efficacy, following concerns raised in its Q2 2026 report. Q2 revenue was $268M, down from $452M, but excluding a $280M one-time Ono payment, revenue rose ~56%. Ionis reported a $115M net loss. FDA approved Tryngolza (June 24) and Dawnzera sales rose 63% sequentially; management reiterated 2026 revenue guidance of $875M to $900M. Analysts maintain a strong buy and a $115 target.

A study in the Journal of Cell Biology, led by Cancer Research UK Scotland Institute and University of Glasgow researchers, describes how Ionis Pharmaceuticals’ antisense oligonucleotide cET-ASOKRas enters pancreatic cancer cells via CD44, activates EPHA2, and is delivered near the nucleus. Blocking CD44 or EPHA2 reduced KRAS suppression and tumor growth; inhibiting stress granules with ISRIB enhanced effects.

Biogen and Ionis’ tofersen (Qalsody) for SOD1-ALS is linked to stabilization or improvement in some patients, including a reported case of reversal after dose escalation. Qalsody was FDA approved in April 2023 based on biomarker data and is marketed in the US and Canada. AL-S Pharma’s AP-101 is also in trials.

Ionis Pharmaceuticals (IONS) reported Q2 2026 total revenue of $268 million, up 56% excluding a one-time Sapablursen payment. Commercial revenue was $119 million, driven by DAWNZERA sales of $26 million (+63% QoQ). 2026 guidance: $875 million to $900 million revenue and non-GAAP operating loss of $425 million to $475 million. Cash was $2.1 billion.

Ionis Pharmaceuticals director Michael R. Hayden bought 20,000 shares of IONS on July 30-31, 2026 at a weighted average $52.94 per share, totaling about $1.1 million, per an SEC Form 4. Holdings rose from 58,298 to 78,298 shares. Ionis reported trailing-twelve-month revenue of $873.8 million and a net loss of $564.8 million, per the article.

AstraZeneca and Ionis’ Wainua failed to show significant cardiovascular benefit in a Phase 3 trial in ATTR-CM, an outcome analysts said likely reduces odds of filing for that indication. The article reviews other ATTR-CM programs: AstraZeneca’s cliramitug (DepleTTR-CM, ~1,200 patients), Novo Nordisk’s coramitug (CLEOPATTRA, recruiting), Alnylam’s nucresiran (TRITON-CM, completion 2030), and Intellia’s nex-z (MAGNITUDE).

Ionis Pharmaceuticals said Frank Bennett, its executive VP and chief scientific officer, will retire effective February 2027 and remain as a strategic consultant during the transition. Ionis credited him with work on antisense oligonucleotides and discovery of drug candidates, including SPINRAZA and QALSODY. Eric Swayze will assume Bennett’s research responsibilities.